Kaliumbromid Desitin (Potassium Bromide)

Potassium bromide enhances the inhibitory action of the neurotransmitter GABA in the central nervous system. By increasing neuronal inhibition, it reduces the likelihood of abnormal electrical discharges that cause seizures, although the exact molecular target remains incompletely defined.

The dosage of potassium bromide is individualized and determined by the prescribing clinician based on the patient’s age, weight, seizure type, and serum bromide levels. Physicians adjust the dose to achieve therapeutic effect while minimizing toxicity.

Safety data for potassium bromide in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Potassium bromide offers a distinct mechanism by enhancing GABA‑mediated inhibition, which can be beneficial for patients who do not respond to sodium channel blockers or other classes. It is generally used as an adjunct rather than a first‑line agent, and its side‑effect profile differs, featuring more sedation and metabolic effects.

Store Kaliumbromid Desitin at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight to maintain stability.

Kaliumbromid Desitin is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule is individualized based on therapeutic response and serum bromide monitoring.

Serious risks include severe depression, respiratory depression, hepatic dysfunction, blood dyscrasias, and rare but life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored regularly for any signs of these adverse events.

Potassium bromide is contraindicated in individuals with known hypersensitivity to bromide salts, severe hepatic or renal impairment, and in patients where alternative, safer anticonvulsants are available. Clinicians should also avoid use in pregnant or lactating women unless the benefits clearly outweigh the risks.